Answers are grounded in this paper and cite their sources.
Host-cell proteins (HCPs) are critical process-related impurities in the manufacture of recombinant biopharmaceuticals because residual HCPs may compromise product stability, efficacy, and patient safety. Consequently, regulatory authorities require effective monitoring and control of HCPs contamination throughout downstream processing. In this study, the performance of two orthogonal polishing operations, hydrophobic interaction chromatography (HIC) and tangential-flow filtration (TFF), was evaluated for HCPs removal during the purification of recombinant human epidermal growth factor (rh-EGF). HIC using Toyopearl Butyl-650C resin achieved a 6.5-fold reduction in HCPs content while maintaining 97% product purity and 71% recovery. Subsequent TFF using sequential 30 and 2 kDa membrane cassettes operated at 12 diavolumes further reduced HCPs content to 50 ng mg⁻¹ product while preserving 97% purity and 67% recovery. The integrated purification process resulted in an overall yield of 11.6 mg rh-EGF L⁻¹ fermentation broth. Sequential application of HIC and TFF reduced residual HCPs levels below the commonly accepted threshold of 100 ng mg⁻¹ protein. These results demonstrate that HIC and TFF provide complementary and orthogonal mechanisms for impurity clearance and constitute a robust downstream strategy for controlling HCPs contamination during laboratory-scale rh-EGF production. The process establishes a foundation for future scale-up and industrial implementation.
No takes yet. Share an insight, caveat, or question.
Hernández et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: